Intravenous administration of EIP‐22 significantly reduced the growth, tumor weight, Ki‐67 proliferation index, and CD31‐positive microvessels, altered circ‐CUX1 target gene expression, and decreased the glucose uptake, lactate production, and ATP levels in subcutaneous xenograft tumors formed by injection of SH‐SY5Y cells (Fig 6G and Appendix Fig S10A–C). This evidence concerns the gene PECAM1 and neoplasm.